The US Food and Drug Administration approved Luye Pharma's (HKG:2186) investigational new drug application for its LY03020 drug for schizophrenia, according to a Tuesday filing with the Hong Kong Exchange.
The approval means the drug could undergo clinical trials in the US, the filing said.
LY03020 is also undergoing clinical trials in China, Luye said.
Shares of the company declined nearly 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.